Immunotherapy for hormone receptor-positive HER2-negative breast cancer

被引：0

作者：

Cardoso, Fatima ^{[1
]}

Hirshfield, Kim M. ^{[2
]}

Kraynyak, Kimberly A. ^{[2
]}

Tryfonidis, Konstantinos ^{[2
]}

Bardia, Aditya ^{[3
]}

机构：

[1] Champalimaud Fdn, Champalimaud Clin Ctr, Breast Unit, Lisbon, Portugal

[2] Merck & Co Inc, Rahway, NJ USA

[3] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Dept Med, Div Hematol Oncol, Los Angeles, CA USA

来源：

NPJ BREAST CANCER | 2024年 / 10卷 / 01期

关键词：

PEMBROLIZUMAB PLUS CHEMOTHERAPY; TUMOR-INFILTRATING LYMPHOCYTES; ADJUVANT ENDOCRINE THERAPY; OPEN-LABEL; HIGH-RISK; NEOADJUVANT CHEMOTHERAPY; LOCALLY RECURRENT; NIVOLUMAB NIVO; TRIAL; PALBOCICLIB;

D O I：

10.1038/s41523-024-00704-9

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Additional therapies are needed to improve outcomes in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer. Research on the potential role of immunotherapy, particularly programmed cell death protein 1/programmed cell death ligand 1 inhibitors, is rapidly expanding in both the early and metastatic settings with some preliminary evidence suggesting benefit when used as part of combination therapy. Several ongoing phase 3 studies should help define their future role in treating these patients.

引用

页数：15

共 92 条

[1] New Advances in Targeted Therapy of HER2-Negative Breast Cancer
An, Junsha
Peng, Cheng
Xie, Xiaofang
Peng, Fu
[J]. FRONTIERS IN ONCOLOGY, 2022, 12
[2] Current Landscape of Targeted Therapy in Hormone Receptor-Positive and HER2-Negative Breast Cancer
Andrahennadi, Samitha
Sami, Amer
Manna, Mita
Pauls, Mehrnoosh
Ahmed, Shahid
[J]. CURRENT ONCOLOGY, 2021, 28 (03) : 1803 - 1822
[3] Durvalumab compared to maintenance chemotherapy in metastatic breast cancer: the randomized phase II SAFIR02-BREAST IMMUNO trial
Bachelot, Thomas
Filleron, Thomas
Bieche, Ivan
Arnedos, Monica
Campone, Mario
Dalenc, Florence
Coussy, Florence
Sablin, Marie-Paule
Debled, Marc
Lefeuvre-Plesse, Claudia
Goncalves, Anthony
Reynier, Marie-Ange Mouret
Jacot, William
You, Benoit
Barthelemy, Philippe
Verret, Benjamin
Isambert, Nicolas
Tchiknavorian, Xavier
Levy, Christelle
Thery, Jean-Christophe
L'Haridon, Tifenn
Ferrero, Jean-Marc
Mege, Alice
Del Piano, Francesco
Rouleau, Etienne
Tran-Dien, Alicia
Adam, Julien
Lusque, Amelie
Jimenez, Marta
Jacquet, Alexandra
Garberis, Ingrid
Andre, Fabrice
[J]. NATURE MEDICINE, 2021, 27 (02) : 250 - +
[4] A Phase II Study of Pembrolizumab in Combination With Palliative Radiotherapy for Hormone Receptor-positive Metastatic Breast Cancer
Barroso-Sousa, Romualdo
Krop, Ian E.
Trippa, Lorenzo
Tan-Wasielewski, Zhenying
Li, Tianyu
Osmani, Wafa
Andrews, Chelsea
Dillon, Deborah
Richardson, Edward T., III
Pastorello, Ricardo G.
Winer, Eric P.
Mittendorf, Elizabeth A.
Bellon, Jennifer R.
Schoenfeld, Jonathan D.
Tolaney, Sara M.
[J]. CLINICAL BREAST CANCER, 2020, 20 (03) : 238 - 245
[5] Discordance of PD-L1 status between primary and metastatic breast cancer: A systematic review and meta-analysis
Boman, Caroline
Zerdes, Ioannis
Martensson, Kira
Bergh, Jonas
Foukakis, Theodoros
Valachis, Antonios
Matikas, Alexios
[J]. CANCER TREATMENT REVIEWS, 2021, 99
[6] Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials
Braybrooke, Jeremy
Bradley, Rosie
Gray, Richard
Hills, Robert K.
Pan, Hongchao
Peto, Richard
Dodwell, David
McGale, Paul
Taylor, Carolyn
Aihara, Tomohiko
Anderson, Stewart
Yothers, Greg
Blum, Joanne
O'Shaughnessy, Joyce
Cardoso, Fatima
Chen, Xiaosong
Crown, John
Ejlertsen, Bent
Jensen, Maj-Britt
Friedl, Thomas W. P.
Janni, Wolfgang
Harbeck, N.
Mamounas, Eleftherios
Narui, K.
Nitz, Ulrike
Norton, Larry
Piccart, Martine
Robert, Nicholas
Shao, Zhi-Ming
Yu, Ke-Da
Slamon, Dennis
Sparano, Joseph
Watanabe, Toru
Bergh, Jonas
Swain, Sandra
Berry, R.
Boddington, C.
Bradley, R.
Clarke, M.
Davies, C.
Davies, L.
Dodwell, D.
Duane, F.
Evans, V.
Gay, J.
Gettins, L.
Godwin, J.
Gray, R.
Hills, R. K.
James, S.
[J]. LANCET, 2023, 401 (10384) : 1277 - 1292
[7] KEYNOTE-756: Phase III study of neoadjuvant pembrolizumab (pembro) or placebo (pbo) plus chemotherapy (chemo), followed by adjuvant pembro or pbo plus endocrine therapy (ET) for early-stage high-risk ER+/HER2e breast cancer
Cardoso, F.
McArthur, H. L.
Schmid, P.
Cortes, J.
Harbeck, N.
Telli, M. L.
Cescon, D. W.
O'Shaughnessy, J.
Fasching, P.
Shao, Z.
Loirat, D.
Park, Y. H.
Fernandez, M. E. Gonzalez
Liu, Z.
Yasojima, H.
Ding, Y.
Jia, L.
Karantza, V. V.
Tryfonidis, K. E.
Bardia, A.
[J]. ANNALS OF ONCOLOGY, 2023, 34 : S1260 - S1261
[8] 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)
Cardoso, F.
Paluch-Shimon, S.
Senkus, E.
Curigliano, G.
Aapro, M. S.
Andre, F.
Barrios, C. H.
Bergh, J.
Bhattacharyya, G. S.
Biganzoli, L.
Boyle, F.
Cardoso, M-J
Carey, L. A.
Cortes, J.
El Saghir, N. S.
Elzayat, M.
Eniu, A.
Fallowfield, L.
Francis, P. A.
Gelmon, K.
Gligorov, J.
Haidinger, R.
Harbeck, N.
Hu, X.
Kaufman, B.
Kaur, R.
Kiely, B. E.
Kim, S-B
Lin, N. U.
Mertz, S. A.
Neciosup, S.
Offersen, B., V
Ohno, S.
Pagani, O.
Prat, A.
Penault-Llorca, F.
Rugo, H. S.
Sledge, G. W.
Thomssen, C.
Vorobiof, D. A.
Wiseman, T.
Xu, B.
Norton, L.
Costa, A.
Winer, E. P.
[J]. ANNALS OF ONCOLOGY, 2020, 31 (12) : 1623 - 1649
[9] Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Cardoso, F.
Kyriakides, S.
Ohno, S.
Penault-Llorca, F.
Poortmans, P.
Rubio, I. T.
Zackrisson, S.
Senkus, E.
[J]. ANNALS OF ONCOLOGY, 2019, 30 (08) : 1194 - 1220
[10] Cardoso F, 2023, SAN ANTONIO BREAST C

← 1 2 3 4 5 6 7 8 9 10 →